NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call
NeuroMetrix, Inc. (NASDAQ: NURO) will release its 2022 Q1 financial results on April 26, 2022, before market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuroMetrix, Inc. (NASDAQ: NURO) will release its 2022 Q1 financial results on April 26, 2022, before market opening. A conference call to discuss these results and business developments will take place at 8:00 a.m. Eastern Time on the same day. Participants in the U.S. can access the call by calling 844-787-0799, while international participants can dial 661-378-9630. The earnings press release will be available on the company's Investor Relations webpage. NeuroMetrix focuses on developing non-invasive devices for pain and neurological disorders.
Positive
- The upcoming earnings release may provide insight into financial performance and business developments.
- NeuroMetrix has a portfolio of three commercial products targeting significant healthcare needs.
Negative
- None.
Details
News Market Reaction – NURO
The recorded move for NURO in the trading session of this news was +4.23%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on April 26, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on April 26, 2022 to discuss its financial results as well as business developments affecting the Company.
The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 5754338. Internationally, the conference call may be accessed by dialing 661-378-9630 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at www.NeuroMetrix.com under the "Investor Relations" tab.
A replay of the conference call will be available starting two hours after the call by dialing 855-859-2056, domestically and 404-537-3406, internationally. The confirmation code to access the replay is 5754338. The replay will be available for one week after the conference call.
About NeuroMetrix
NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of entrapment neuropathies. Quell® is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain. For more information, visit www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.